30 closest matches · ranked by relevance
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
HIV Related Insulin Resistance · Protease Inhibitor Related Insulin Resistance · Endoplasmic Reticulum Stress
Primary: Glucose Uptake — 0; 8 change in glucose infusion rate (ml/hr)
Inflammation · Macrophage Infiltration · Cardiovascular Disease
Primary: Inflammatory Biomarker 1: Plasma hsCRP Concentration — 3.4; 5.4; 2.9; 7.4 mg/L — p=0.006
HIV Lipodystrophy
Primary: Insulin Resistance (HOMA Index) — 1.6; 1.8 units on a scale
HIV Infections · Cardiovascular Disease · Insulin Resistance
Primary: Myocardial Glucose Utilization Rate — 109.6; 106.7; 109.1; 87.2 (nmol glucose/g heart muscle/min
HIV-Associated Lipodystrophy Syndrome · Insulin Resistance · HIV Infections
Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1
HIV Infections · Metabolic Syndrome X
Primary: Carotid Intima Media Thickness — -0.02; -0.02; 0.00; 0.03 mm — p=0.37
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
HIV Infections · Type 2 Diabetes · Obesity
Primary: Insulin-stimulated Glucose Disposal Rate — 30; 34; 37; 48 µmol glucose/kg FFM/min
HIV Infections
Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
HIV-1 and Hepatitis C Co-Infection
Primary: The Proportion of All Subjects With HCV Viral Load < 60 IU/mL at Week 24 of Step 2. — 0.158 proportion of participants — p=0.29
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
HIV · HIV Lipodystrophy
Primary: Liver Fat — -2.0; 0.9 Change in hepatic lipid-to-water %
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Mitochondrial Function (mtDNA Levels) — 1372 copies per cell
Diabetes · Metabolic Syndrome · Insulin Resistance
Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale
HIV Infection
Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2
Inflammation · Insulin Resistance
Primary: Insulin Signaling With Lipid Infusion — 0.4334; 0.7276; 0.5264; 0.3534 ratio
Insulin Resistance · Postmenopause
Primary: Percent Change in Free Testosterone (T) — -6.9; -35.8; 12.1 percent change
HIV-1-infection on Healthy Volunteers
Primary: Change in Insulin Sensitivity in Participants From Baseline to End of Study Between Two Crossover Groups. — 7.749985; 6.286017; 8.716221; 6.815305 (mg/kg/min)
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Insulin Resistance
Primary: Linear Relationship Between HOMA-IR and Cognitive Function (R-squared) — 0.205; 0.299; 0.738; 0.0264 R-squared — p=0.162
Type 2 Diabetes · Insulin Resistance · Metabolic Syndrome
Primary: Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR) — 17.95; 1.68 micromols/kg of FFM/minute — p=<0.001
Diabetes · Insulin Resistance
Primary: CD4+ T-cell Count — 602; 648; 689; 750 cells/µL — p=>0.05
HIV
Primary: Insulin Stimulated Glucose Uptake — 7.70; 8.58 mg/min per μIU/ml — p=0.71
HIV Infections
Primary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02
HIV Infections · Lipodystrophy
Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001